The Trump administration's direct-to-consumer drug price aggregation platform, TrumpRx , has been operating for more than six months, but a new survey of managed care professionals suggests widespread skepticism about whether it delivers real savings for patients. In the first part of a video interview with Pharmaceutical Commerce, Adam Colborn, vice president of government affairs at the Academy of Managed Care Pharmacy (AMCP), breaks down the results of AMCP's member survey on TrumpRx and what they reveal about the platform's reception among managed care professionals. TrumpRx launched in February as a White House initiative billed as a way to give patients access to discounted drugs priced in line with what other developed nations pay, a policy the administration calls most favored nation pricing. Colborn notes that AMCP's respondents are not typically the type of healthcare professional who would refer a patient to TrumpRx. He also notes the Federal Trade Commission's settlements with PBMs, including Express Scripts, which required standard plan offerings to eventually count TrumpRx purchases toward a patient's deductible once the regulatory groundwork is in place.3 Colborn says the results of the survey potentially indicate a disconnect between how TrumpRx is being marketed and how managed care professionals view its real-world value.